Phaseline

Targets › AGTR2

AGTR2 (Type-2 angiotensin II receptor): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Respiratory; next expected readout May 2027.

Receptor for angiotensin II, a vasoconstricting peptide. Primarily signals via a non-canonical G protein- and beta-arrestin independent pathways. (UniProt, P50052)

Open in Phaseline: the race on AGTR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vicore PharmaBuloxibutid
Angiotensin II type 2 receptor agonist
AGTR2Phase 2Idiopathic Pulmonary Fibrosis (IPF)May 2027

Conditions

Idiopathic Pulmonary Fibrosis (IPF) (1)

Modalities

small molecule (1)

Companies

Vicore Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.